HR23B, a biomarker for HDAC inhibitors
<p>As our understanding of cancer biology increases and novel therapies are developed, an increasing number of predictive biomarkers are becoming clinically available. Aberrant acetylation has been strongly linked to tumourigenesis and the modulation of acetylation through targeting histone d...
Auteur principal: | Khan, OA |
---|---|
Autres auteurs: | La Thangue, NB |
Format: | Thèse |
Langue: | English |
Publié: |
2013
|
Sujets: |
Documents similaires
-
Mitochondrial modulators of hypoxia-related pathways in tumours
par: Snell, CE
Publié: (2013) -
Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
par: New, M
Publié: (2014) -
Angiogenesis in human lung tumours
par: Ferguson, ML
Publié: (2008) -
Risk factors for haemorrhage in patients with haematological malignancies
par: Estcourt, LJ
Publié: (2014) -
Regulation of stemness and differentiation in colorectal cancer
par: Gandhi, S
Publié: (2010)